Fluticasone Propionate

Summary

Fluticasone Propionate (CHEMBL1473) is an approved small-molecule anti-allergic agent (ATC D07AC17) targeting NR3C1, NR3C2, and PGR; indicated across 24 conditions including chronic obstructive pulmonary disease and allergic rhinitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AC17 (+3 more)
• Targets: 3 (NR3C1, NR3C2, PGR)
• Indications: 24 conditions
• Clinical trials: 245
• Chemistry: 500.6 Da · C25H31F3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1473
Name	Fluticasone Propionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	444036
ChEBI	CHEBI:31441
ATC	D07AC17, R01AD08, R03BA05, R01AD58
Molecular formula	C25H31F3O5S
Molecular weight	500.6
InChIKey	WMWTYOKRWGGJOA-CENSZEJFSA-N

SMILES: CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF

IUPAC name: [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate

ChEBI definition: A trifluorinated corticosteroid that consists of 6α,9-difluoro-11β,17α-dihydroxy-17β-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.

Pharmacological roles (ChEBI): anti-allergic agent, anti-asthmatic drug, anti-inflammatory drug, dermatologic drug, bronchodilator agent, adrenergic agent.

Also known as: Aerivio spiromax, Airflusal forspiro, Armonair digihaler, Armonair respiclick, CCI 18781, CCI-18781, CCI18781, Cutivate, Flixonase, Flixotide, Flonase, Flonase allergy relief

Patent coverage: 14,606 distinct patent families (60,190 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR3C1	Glucocorticoid receptor	Agonist	8.05	0.9%	P04150
NR3C2	Mineralocorticoid receptor	Agonist	6.83	0%	P08235
PGR	Progesterone receptor	Agonist	7.68	0.1%	P06401

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Androgen receptor, Mineralocorticoid receptor, Glucocorticoid receptor, Progesterone receptor, Adenosine receptor A3, Glucocorticoid receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 17 potent at pChembl ≥ 5 of 18 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	10.4	IC50	0.04	nM	CHEMBL_ACT_18140877
NR3C1	10.36	IC50	0.04	nM	CHEMBL_ACT_18140935
NR3C1	10.12	IC50	0.07	nM	CHEMBL_ACT_7934510
P06536	9.85	IC50	0.14	nM	CHEMBL_ACT_18140976
NR3C1	9.3	IC50	0.5	nM	CHEMBL_ACT_744321
NR3C1	9.15	EC50	0.7	nM	CHEMBL_ACT_7934447
P06536	9.12	EC50	0.76	nM	CHEMBL_ACT_7934470
NR3C1	9.05	IC50	0.9	nM	CHEMBL_ACT_18141076
NR3C1	8.96	EC50	1.09	nM	CHEMBL_ACT_6390730
NR3C1	8.89	AC50	1.3	nM	CHEMBL_ACT_25175975
PGR	8.42	AC50	3.8	nM	CHEMBL_ACT_25204525
P06536	8.3	IC50	5	nM	CHEMBL_ACT_1188299
PGR	8	AC50	10	nM	CHEMBL_ACT_25223141
PGR	7.68	IC50	21	nM	CHEMBL_ACT_18141097
AR	6.88	AC50	130.7	nM	CHEMBL_ACT_25203592
NR3C2	6.83	IC50	149	nM	CHEMBL_ACT_18141062
NR1I2	6	AC50	1000	nM	CHEMBL_ACT_25188274

Target pathways

Aggregated over 3 target gene(s): NR3C1, NR3C2, PGR.

Top Reactome pathways

18 total, by targets touching each:

Pathway	Targets	Genes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	3	NR3C1, NR3C2, PGR
Nuclear Receptor transcription pathway	3	NR3C1, NR3C2, PGR
SUMOylation of intracellular receptors	3	NR3C1, NR3C2, PGR
Nuclear signaling by ERBB4	1	PGR
Cellular responses to stress	1	NR3C2
SUMOylation	1	NR3C2
SUMO E3 ligases SUMOylate target proteins	1	NR3C2
Metabolism of proteins	1	NR3C2
Post-translational protein modification	1	NR3C2
PTK6 Expression	1	NR3C1
Regulation of RUNX2 expression and activity	1	NR3C1
Cellular responses to stimuli	1	NR3C2
Estrogen-dependent gene expression	1	PGR
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	1	NR3C1
Potential therapeutics for SARS	1	NR3C1
Regulation of NPAS4 gene transcription	1	NR3C1
Developmental Lineage of Mammary Gland Luminal Epithelial Cells	1	PGR
Developmental Lineage of Mammary Gland Alveolar Cells	1	PGR

Dominant GO biological processes

GO term	Targets
regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	3
signal transduction	3
nuclear receptor-mediated steroid hormone signaling pathway	3
positive regulation of transcription by RNA polymerase II	2
negative regulation of transcription by RNA polymerase II	1
regulation of gluconeogenesis	1
chromatin organization	1
apoptotic process	1
chromosome segregation	1
glucocorticoid metabolic process	1
response to wounding	1
gene expression	1
microglia differentiation	1
adrenal gland development	1

Indications & clinical

Indications

24 indications (12 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	4	MONDO:0005002	EFO:0000341
allergic rhinitis	4	MONDO:0011786	EFO:0005854
nasal cavity polyp	4	MONDO:0006314	EFO:1000391
seasonal allergic rhinitis	4	MONDO:0005324	EFO:0003956
obstructive lung disease	4	MONDO:0002267	HP:0006536
pulmonary emphysema	4	MONDO:0004849	EFO:0000464
skin disorder	4	MONDO:0005093	EFO:0000701
atopic eczema	4	MONDO:0004980	EFO:0000274
chronic bronchitis	4	MONDO:0005607	EFO:0006505
asthma	4	MONDO:0004979	MONDO:0004979
eosinophilic esophagitis	3	MONDO:0005361	EFO:0004232
perennial allergic rhinitis	3	MONDO:0024332	EFO:1001417
bronchiolitis obliterans syndrome	3	MONDO:0015265	EFO:0007183
sinusitis	3	MONDO:0005961	EFO:0007486
chronic rhinosinusitis	3	MONDO:0006031	EFO:1000024
bronchiolitis	2	MONDO:0002465	HP:0011950
polyp	2	MONDO:0005079	EFO:0000662
bronchogenic carcinoma	2	MONDO:0002806	EFO:1001942
rhinitis	2	MONDO:0003014	EFO:0008521
blepharitis	2	MONDO:0004785	EFO:0009536
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 245.

Phase distribution

Phase	Trials
PHASE3	73
PHASE4	63
PHASE2	39
PHASE1	33
Not specified	29
PHASE2/PHASE3	7
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02476825	PHASE4	ACTIVE_NOT_RECRUITING	A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers
NCT00071552	PHASE4	TERMINATED	Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
NCT00102765	PHASE4	COMPLETED	Study Of Asthma In Patients Of African Descent
NCT00102882	PHASE4	COMPLETED	Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
NCT00115492	PHASE4	COMPLETED	Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
NCT00118690	PHASE4	COMPLETED	A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
NCT00118716	PHASE4	COMPLETED	A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
NCT00119015	PHASE4	TERMINATED	The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis
NCT00120978	PHASE4	UNKNOWN	Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial
NCT00144911	PHASE4	COMPLETED	ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
NCT00169546	PHASE4	COMPLETED	Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.
NCT00184977	PHASE4	COMPLETED	COPD on Primary Care Treatment (COOPT)
NCT00197106	PHASE4	COMPLETED	Treatment Of Symptomatic Asthma In Children
NCT00273026	PHASE4	TERMINATED	Study In Asthma Control
NCT00296491	PHASE4	COMPLETED	Study Of Allergic Rhinitis In Patients Who Also Have Asthma
NCT00296530	PHASE4	COMPLETED	Study Of Patients With Allergic Rhinitis And Asthma
NCT00315744	PHASE4	COMPLETED	Viapaed Study In Children And Adolescents With Asthma
NCT00346749	PHASE4	TERMINATED	ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.
NCT00351143	PHASE4	COMPLETED	A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control
NCT00353873	PHASE4	COMPLETED	Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids
NCT00355342	PHASE4	COMPLETED	Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
NCT00358358	PHASE4	COMPLETED	Chronic Obstructive Pulmonary Disease Endpoints Study
NCT00361959	PHASE4	COMPLETED	SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
NCT00452348	PHASE4	COMPLETED	A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
NCT00452699	PHASE4	COMPLETED	A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
NCT00455923	PHASE4	COMPLETED	SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
NCT00456313	PHASE4	WITHDRAWN	No Resistance After Long Term Treatment SERETIDE
NCT00461500	PHASE4	COMPLETED	SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
NCT00480649	PHASE4	COMPLETED	Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)
NCT00487032	PHASE4	COMPLETED	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation
NCT00503009	PHASE4	TERMINATED	Study Of RV-39 In Patients Who Also Have Asthma
NCT00546000	PHASE4	COMPLETED	Cutivate Lotion HPA Axis Pediatric Study
NCT00616538	PHASE4	COMPLETED	Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis
NCT00633217	PHASE4	COMPLETED	Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
NCT00712335	PHASE4	COMPLETED	The Effects of Montelukast on Smokers With Asthma
NCT00784550	PHASE4	COMPLETED	A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
NCT00845598	PHASE4	WITHDRAWN	Azelastine Fluticasone Combination vs. Fluticasone
NCT00848965	PHASE4	COMPLETED	A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
NCT00975195	PHASE4	COMPLETED	Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
NCT00984659	PHASE4	COMPLETED	Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 20 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

345 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ENZALUTAMIDE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2, PGR
EPLERENONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2, PGR
FLUDROCORTISONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2, PGR
BUDESONIDE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
HYDROCORTISONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
HYDROCORTISONE BUTYRATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
PREDNISOLONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
PROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
ASOPRISNIL	ChEMBL	Phase 3	NR3C1, NR3C2, PGR
METRIBOLONE	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
ONAPRISTONE	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
STANOLONE	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
TUROFEXORATE ISOPROPYL	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
FULVESTRANT	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
PODOFILOX	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
ALCLOMETASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
AMCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BENZBROMARONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BETAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BETAMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BETAMETHASONE VALERATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CANRENONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CHLORMADINONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CICLESONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CLOBETASOL PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DANAZOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DEFLAZACORT	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESOGESTREL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESOXIMETASONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESOXYCORTICOSTERONE PIVALATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DIFLORASONE DIACETATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DOXORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DROSPIRENONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ECONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
EFAVIRENZ	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ESTRADIOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ESTRIOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
EXEMESTANE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FELODIPINE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUNISOLIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOCINOLONE ACETONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOROMETHOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOXYMESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLURANDRENOLIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
HALCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR